Efficacy and Safety of Botulinum Toxin Type A in Treating Patients of Advanced Age with Idiopathic Trigeminal Neuralgia.

Jing LiuYing-Ying XuQi-Lin ZhangWei-Feng Luo

Published in: Pain research & management (2018)

BTX-A is effective and safe in treating patients of advanced age (≥80 years old) with ITN, at dosages comparable to those used in much younger counterparts (<60 years old).

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
botulinum toxin
prognostic factors
spinal cord injury